Short answer
Progyny, Inc. (PGNY) filed its Q3 2025 10-Q quarterly report on Nov 7, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $313M (up 9.3% year over year) with net income of $14M.
Q3 2025 key financials · XBRL
- Revenue
- $313M
- +9.3% YoY · −5.9% QoQ
- Net income
- $14M
- +33.0% YoY · −19.0% QoQ
- Operating margin
- 6.9%
- Gross margin
- 23.2%
- EPS (diluted)
- $0.15
- +25.0% YoY · −21.1% QoQ
Source: XBRL data from the Progyny, Inc. (PGNY) Q3 2025 10-Q on SEC EDGAR. USD.
Progyny, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No newly added risk factors disclosed; risk section restates prior known risks without material update
- Most materially updated risk: client contract renewal risk heightened by a large client non-renewal with transition ending June 30, 2025
- Legal/compliance risk: income tax expense rose 45% YoY to $31.5M YTD, reflecting greater U.S. and foreign tax obligations and deferred tax asset realizability considerations
- Operational/market risk: 9% revenue growth driven by client base expansion to 553 clients and 6.7M covered lives, but utilization rates slightly declined to 0.54% in Q3 2025
- Financial risk: modest 6% cost of services increase driven by higher medical and pharmacy costs and incremental headcount, partially offset by a $0.3M stock-based comp decline
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Progyny, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.